Clozapine is known as the first `atypical' medication and is effective in people who have treatment-resistant schizophrenia. Its 1990 emergence in the USA was marked by considerable controversy over its high cost, due in large part to having been both the first new antipsychotic medication to come to market in over a decade and the need for comprehensive safety monitor ing within a decentralized health system. This paper traces the histor y of clozapine's discover y and development in Europe, its part in the 1975 Finnish agranulocytosis scare, and its subsequent volatile emergence in the USA. Analyses examine peripheral forces at the time, particularly the influence of political, corporate, medical and societal forces which shaped its market course.
Adams, M.E., Chang, H. and Frazier, H.S. (1995) Clozapine therapy for schizophrenia. In J. D. Graham and J. B. Wienert (eds), Risk vs. Risk: Tradeoffs in Protecting Health and the Environment (Cambridge, MA: Harvard University Press), 53—71.
2.
Amsler, H.A., Teerenhovi, L., Barth E., Harjula, K. and Vuopio, P. (1977) Agranulocytosis in patients treated with Clozaril: a study of the Finnish epidemic. Acta Psychiatrica Scandanavica , 56, 241—8.
3.
Anderman, B. and Griffith, R.W. (1977) Clozapine-induced agranulocytosis: a situation report up to August 1976. European Jour nal of Clinical Pharmacology , 11, 199—201.
4.
Ayd, F.J. (1974) Clozapine: a unique new neuroleptic. Inter national Drug TherapyNewsletter, 9, 5—12.
5.
Baldessarini, R.J. and Frankenburg, F.R. (1991) Clozapine: a novel antipsychotic agent. New England Jour nal ofMedicine, 324(11), 746—54.
6.
Caine, E.D. (2005) Personal interview by author, 3 Aug. 2005.
7.
Caine, E.D., Polinsky, R.J., Kartzinel, R. and Ebert, M.H. (1979) The trial use of clozapine for abnormal involuntary movement disorders. American Jour nal of Psychiatry,136, 317—20.
8.
Chirico, A., Carfagno, S. and Lytel, F. (1957) Agranulocytosis after promazine therapy. New England Jour nal ofMedicine, 256, 899.
9.
Claghorn, J.L., Abuzzahab, F.S., Wang, R., Larson, C., Gelenberg, A.J., Klerman, G.L., Tuason, V. and Steinbook, R. (1983) The current status of clozapine. Psychopharmacology Bulletin, 19(1), 138—40.
10.
de la Chapelle, A., Kari, C., Nurminen, M. and Hernberg, S. (1977) Clozapine-induced agranulocytosis: an epidemiological and genetic study. Human Genetics, 37, 183—94.
11.
Fda (1997) [News Release] FDA Advisor y Committee Recommends New Clozaril Monitoring Guidelines, 16 July .
12.
Gerlach, J., Koppelhus, P., Helweg, E. and Monrad, A. (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia . Acta Psychiatrica Scandanavica, 50, 410—24.
13.
Griffith, R.W. and Saameli, K. (1975) Clozapine and agranulocytosis, The Lancet, 2 (7936, 4 Oct.), 657.
14.
Gross, V.H. and Langner, E. (1966) Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wiener Medizinische Wochenschrift , 40, 814—16.
15.
Hippius, H. (1989) The history of clozapine. Psychopharmacology , 99, S3—5.
16.
Hippius, H. (1999) A historical perspective of clozapine. Jour nal of Clinical Psychiatr y, 60 (suppl. 12), 22—3.
17.
Honigfeld, G. (2005) Personal interview by author, 1—2 Aug. 2005 .
18.
Hyde, T.M. and Weinberger, D.R. (1990) The brain in schizophrenia. Seminars in Neurology, 10(3), 276—86.
19.
Idanpaan-Heikkila, J., Alhava, E., Olkinuora, M. and Palva, I.P. (1975) Clozapine and agranulocytosis. The Lancet, 2 (7935, 27 Sept.), 611.
20.
Idanpaan-Heikkila, J.,Alhava, E., Olkinuora, M. and Palva, I.P. (1977) Agranulocytosis during treatment with clozapine. European Jour nal ofClinical Pharmacology, 11, 193—8.
21.
Kane, J.M., Honigfeld, G., Singer, J. and Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry,45, 789—97.
22.
Leber, P. (1981) Sudden death as a risk of neuroleptic treatment: (a continuing controversy). Psychopharmacology Bulletin, 17(3), 6—9.
23.
Leestma, J.E. and Koenig, K.L. (1968) Sudden death and phenothiazines: a current controversy . Archives of General Psychiatry,18, 137—48.
24.
Lehmann, H.E. and Hanrahan, G.E. (1954) Chlorpromazine, new inhibiting agent for psychomotor excitement and manic states. Archives of Neurology and Psychiatry ,71, 227—37.
25.
Leon, C.A. (1979) Therapeutic effects of clozapine: a 4-year follow-up of a controlled clinical trial. Acta Psychiatrica Scandanavica , 59, 471—80.
26.
Liang, B.C. (2002) The drug development process II: investigational new drug application. Hospital Physician, (Aug.), 36—8.
27.
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D. and Severe, J. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Jour nal of Medicine , 353(12), 1209—23.
28.
Lindberg, G.L., Lurie, N.L., Bannick-Moreland, S., Sherman, R.E. and Farseth, P.A. (1989) Health care cost containment measures and monitoring. American Jour nal of PublicHealth, 79(11), 1481—5.
29.
Lomas, J. (1954) Chlorpromazine and agranulocytosis. British Medical Journal,2 (4883), 358.
30.
Lurie, N., Ward, N.B., Shapiro, M.F. and Brook, R.H. (1984) Termination from Medi-Cal: does it affect health? New England Jour nal ofMedicine, 311 (7), 480-4.
31.
Mattison, N. (1986) Pharmaceutical innovation and generic drug competition in the USA: effects of the Drug Price Competition and Patent Term Restoration Act of 1984. Pharmaceutical Medicine, 1, 177—85.
32.
Matz, R., Rick, W. and Oh, D. (1974) A potential antipsychotic agent without extrapyramidal manifestations. Current Therapeutic Research, 7, 687—95.
33.
Metzenbaum, H. (1991) Marketing of Clozaril: improved safety or barrier to access, Subcommittee on Antitrust, Monopolies, and Business Rights (Washington, DC: U.S. Government Printing Office).
34.
Miller, C.A. (1985) Infant mortality in the U.S. Scientific American, 253(1), 31—7.
35.
Parascandola, J. (1992) The Development of American Pharmacology (Baltimore: Johns Hopkins University Press ).
36.
Phelps, C. (1997) Health Economics, 2nd edn (Reading: Addison-Wesley).
37.
Pisciotta, A.V. (1965) Studies on agranulocytosis VII: limited proliferative potential of CPZsensitive patients. Jour nal of Laborator y and ClinicalMedicine, 65(2),240—7.
38.
Pisciotta, A.V., Ebbe, S., Lennon, E.J., Metzger, G.O. and Madison, F.W. (1958) Agranulocytosis following administration of phenothiazine derivatives. American Jour nal ofMedicine, 25, 210—23.
39.
Povlsen, U.J., Noring, U., Fog, R. and Gerlach, J. (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatrica Scandinavica, 71, 176—85.
40.
Reid, W.H. (1990) Access to care: clozapine in the public sector . Hospital and Community Psychiatry,41(8), 870—4.
41.
Reid, W.H. (1994) The treatment of psychosis: resetting the drug cost “thermostat”. Jour nal ofClinical Psychiatry ,55 (9, Suppl. B), 166—8.
42.
Safferman, A., Leiberman, J.A., Kane, J.M., Szymanski, S. and Kinon, B. (1991) Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17(2),247—61.
43.
Sandoz Pharmaceuticals Corp. (1989) CPMS: Professionals' Guide to the Clozaril Patient Management System [original Sandoz Corp. marketing tool].
44.
Schmutz, J. and Eichenberger, E. (1982). Clozapine. In J. S. Bindra and D. Lednicer , Chronicles of Drug Discovery, Vol.1 (New York: John Wiley & Sons ), 39—59.
45.
Shopsin, B., Klein, H., Aaronsom, M. and Collora, M. (1979) Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled double-blind comparison . Archives of General Psychiatry,36, 657—64.
46.
Shorter, E. (1997) A Histor y of Psychiatry:From the Era of the Asylum to the Age of Prozac (New York: John Wiley & Sons).
47.
Simpson, G.M. and Varga, E. (1974) Clozapine — a new antipsychotic agent. Current Therapeutic Research, 16(7), 679—95.
48.
Starr, P. (1982) The Social Transfor mation of Amer ican Medicine (Princeton, NJ: Basic Books).
49.
Stephens, P. (1990) A review of clozapine: an antipsychotic for treatment-resistant schizophrenia. Comprehensive Psychiatry,31(4), 315—26.
50.
Stille, G. and Hippius, H. (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatry,4, 182—91.
51.
Stockman, D.A. (1981) Premises for a medical marketplace: a neoconservative's vision of how to transform the health system. Health Affairs , 1 (1), 5-18.
52.
Todd, J.S., Seekins, S.V., Krichbaum, J.A. and Harvey, L.K. (1991) Health access America — strengthening the US health care system. Jour nal of the American Medical Association , 265(19), 2503—6.
53.
van Kammen, D.P. and Marder, S.R. (2000). Serotonin-dopamine antagonists. In B. Sadock and V. Sadock, Comprehensive Textbook of Psychiatry, Vol. II, 7th edn (Philadelphia: Lippincott Williams &Wilkins), 2455—6.
54.
Van Rossum, J.M., Janssen, P.A. and Boissier, J.R. (1970) Pharmacology. Moder n Problems in Pharmacopsychiatry, 5, 23—70.
